DSA
Dual Stem cell Activation

Dual Stem Cell Activation (DSA) involves the simultaneous application of two types of autologous stem cells (SC) – mesenchymal and hematopoietic SC. They are derived from bone marrow (predominantly mesenchymal) and peripheral blood (mostly hematopoietic). The capacity of SC for differentiation, immunomodulation, and angiogenesis renders them potent therapeutic agents in the field of regenerative reproductive medicine.

DSA therapy results in the improvement of hormonal levels, follicular activation, angiogenesis, and functional restoration of the ovary. Stem cells can differentiate into various types of cells, including ovarian cells. They also have angiogenic potential, meaning they can promote the formation of new blood vessels. Therapy with SC influences hormonal balance in the body and supports the process of folliculogenesis, which is crucial for the formation of healthy follicles and ovulation. Stem cells have anti-inflammatory and antioxidant properties that can reduce inflammation and oxidative stress in the ovaries and endometrium. Additionally, improving the ovarian microenvironment stimulates the growth of healthy egg cells. This results in improved egg quality and reduced risk of genetic
abnormalities in offspring. Stem cell therapy naturally – through autologous factors – improves endometrial receptivity, with a role in endometrial remodelling and positive coordination between embryos and the endometrium, as well as improving endometrial vascularity.

The fundamental principle of DSA is the simultaneous application of two types of stem cells, mesenchymal and hematopoietic, providing synergy and increasing the effects of individual cell types. DSA enables the obtaining of a significantly larger number of SCs with the possibility of cryopreservation and later enhancement of the positive effects of therapy.
​